A PLAIN-LANGUAGE SUMMARYOF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER

Warner Ellen; De laurentiis Michelino; Martin Miguel; Cottu Paul; Lu Janice; Azim Hamdy; Aubel Dawn; Zhou Katie; Wu Jiwen; Menon Lakshmi; Zamagni Claudio

首页> 外文期刊>The Breast : >A PLAIN-LANGUAGE SUMMARYOF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER

【24h】

A PLAIN-LANGUAGE SUMMARYOF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER

机译：Complement-1研究的简单语言摘要：核武杆菌和Letrozole作为第一线治疗，研究了3,246人和晚期乳腺癌的研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《The Breast :》 |2019年第2期|共2页
作者
Warner Ellen; De laurentiis Michelino; Martin Miguel; Cottu Paul; Lu Janice; Azim Hamdy; Aubel Dawn; Zhou Katie; Wu Jiwen; Menon Lakshmi; Zamagni Claudio;
展开▼
作者单位

Sunnybrook Odette Canc Ctr Med Oncol Toronto ON Canada;

Inst Nazl Tumori Fdn Pascale Oncol Naples Italy;

Inst Invest Sanitaria Gregorio Maranon Oncol Madrid Spain;

Inst Curie Oncol Paris France;

Univ Southern Calif Norris Comprehens Canc Ctr Oncol Los Angeles CA USA;

Cairo Univ Sch Med Oncol Cairo Egypt;

Novartis Pharmaceut Global E Hanover NJ USA;

Novartis Pharmaceut Global E Hanover NJ USA;

Novartis Pharmaceut Global E Hanover NJ USA;

Novartis Pharmaceut Global E Hanover NJ USA;

St Orsola Marcello Malpighi Hosp Oncol Bologna Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. A PLAIN-LANGUAGE SUMMARYOF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER [J] . Warner Ellen, De laurentiis Michelino, Martin Miguel, The Breast : . 2019,第Suppla2期

机译：Complement-1研究的简单语言摘要：核武杆菌和Letrozole作为第一线治疗，研究了3,246人和晚期乳腺癌的研究
2. Ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Ribociclib加仑唑醇患者HR +，HER2-先进的乳腺癌：第3B阶段的安全分析 - 1试验
3. RIBOCICLIB (RIB) plus LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL [J] . Farhat Fadi, Martin Miguel, Campone Mario, The Breast : . 2019,第Suppla2期

机译：Ribociclib（肋骨）加仑唑（Let）在激素受体阳性（HR Plus），人体表皮受体-2阴性（HER2-）先进的乳腺癌（ABC）的剂量强度：初步亚组是来自第3B阶段的替代 -1试验
4. Realistic novel breast and breast cancer phantoms for the study of imaging and therapy ultrasound [C] . Arce F., Leija L., Vera A., International Conference on Electrical Engineering, Computing Science and Automatic Control . 2014

机译：用于成像和治疗超声研究的逼真的新型乳腺癌和乳腺癌体模
5. Boron neutron capture therapy applied to advanced breast cancers: Engineering simulation and feasibility study of the radiation treatment protocol. [D] . Sztejnberg Goncalves-Carralves, Manuel Leonardo. 2009

机译：硼中子捕获疗法在晚期乳腺癌中的应用：放射治疗方案的工程模拟和可行性研究。
6. Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study [O] . Christian Rudlowski, Nina Beermann, Lena Leitzen, 2020

机译：在卷虫研究中用核心杆菌/ Letrozole进行前线治疗后局部晚期转移性De Novo乳腺癌的完整临床反应
7. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective [O] . Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne, 2021

机译：Ribociclib的成本效果加仑唑唑与帕尔巴昔克氏菌和Letrozole或Letrozole作为单药治疗后期治疗后期妇女的HR + / Her2-局部晚期或转移性乳腺癌：巴西私人付款人的角度

A PLAIN-LANGUAGE SUMMARYOF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER

著录项

引文网络

相似文献

相关主题

期刊订阅